HealthcareServices

Congenital Heart Disease (CHD) Market Performance Outlook 2026–2030: Revenue to Hit $7.27 Billion at 8.1% CAGR

February 23, 2026February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the congenital heart disease (chd) market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Congenital Heart Disease (CHD) Market’s size between 2026 and 2030?

The congenital heart disease (CHD) market size has demonstrated strong growth in recent years. This market is anticipated to expand from $4.85 billion in 2025 to $5.32 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.7%. Historically, its growth can be linked to the high prevalence of structural birth defects, insufficient early diagnostic capabilities, the necessity for open-heart surgery, elevated infant mortality rates, and the concentration of specialized care in tertiary hospitals.

The congenital heart disease (chd) market size is anticipated to experience substantial growth in the coming years. It is projected to reach $7.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. This expansion during the forecast period can be attributed to advancements in minimally invasive cardiology, improved imaging and diagnostics, an increasing adult chd population, the proliferation of specialized cardiac centers, and rising healthcare investments. Major trends expected in this timeframe include the growth of early prenatal and neonatal screening, the increasing adoption of catheter-based interventions, the expansion of pediatric and adult chd care programs, higher survival rates driving adult chd care needs, and multidisciplinary long-term disease management strategies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp

Which Drivers Are Shaping Strategic Decisions In The Congenital Heart Disease (CHD) Market?

The rising incidence of maternal diabetes is anticipated to fuel the expansion of the congenital heart disease (CHD) market in the coming years. Maternal diabetes, also known as gestational diabetes mellitus (GDM), is a condition where diabetes develops during pregnancy in women who were not diabetic prior to conceiving. This condition is triggered by evolving lifestyles, encompassing sedentary habits and poor nutrition, alongside a general increase in obesity among women of reproductive age. Elevated blood sugar levels from maternal diabetes can adversely impact fetal heart development, potentially resulting in congenital heart disease (CHD) in infants. These increased glucose concentrations in the mother’s bloodstream interfere with the proper formation of the baby’s heart, consequently raising the likelihood of CHD. As an illustration, data from November 2025, provided by the Society For Maternal Fetal Medicine, a US-based organisation, indicates that gestational diabetes mellitus (GDM) affects around 15.6% of women globally, with approximately 23.3 million live births impacted by high blood sugar during pregnancy in 2024. Consequently, the growing number of maternal diabetes cases is a significant factor propelling the expansion of the congenital heart disease (CHD) market.

What Segment Classifications Make Up The Congenital Heart Disease (CHD) Market?

The congenital heart disease (chd) market covered in this report is segmented –

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types

2) By Diagnosis: Electrocardiogram, Chest X-ray, Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis

3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications

4) By Age Group: Infants, Children, Adolescents, Adults

5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:

1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation

2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)

3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus

4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

Which Trends Are Shaping Activity Within The Congenital Heart Disease (CHD) Market?

Leading companies operating in the congenital heart disease market are focused on developing non-surgical heart valves to improve patient outcomes and their quality of life. These non-surgical, also known as transcatheter, heart valves are medical devices that address heart valve diseases without the need for traditional open-heart surgery. For example, Medtronic, a US-based medical technology company, relaunched its Harmony Transcatheter Pulmonary Valve (TPV) System in February 2023. This system offers a groundbreaking, minimally invasive alternative to open-heart surgery for individuals with congenital heart disease, especially those with native or surgically repaired right ventricular outflow tract (RVOT) anomalies. It represents the first FDA-approved valve specifically designed for the right side of the heart, providing a non-surgical option for patients experiencing severe pulmonary valve regurgitation. The Harmony TPV System had originally received U.S. FDA approval in 2021, and its reintroduction following a voluntary recall highlights Medtronic’s dedication to advancing solutions for congenital heart disease patients.

Which Key Market Players Are Investing In Expansion And Innovation Within The Congenital Heart Disease (CHD) Market?

Major companies operating in the congenital heart disease (chd) market are Abbott Laboratories, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Carestream Health, Schiller AG, BPL Medical Technologies, Bionet America Inc., Edwards Lifesciences Corporation, GE Healthcare, BIOTRONIK SE & Co KG, W L Gore & Associates Inc, Cook Medical, Lepu Medical Technology Co Ltd, Getinge AB, Merit Medical Systems Inc, Eurocor Tech GmbH, Braile Biomedica

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Congenital Heart Disease (CHD) Market?

North America was the largest region in the congenital heart disease (CHD) market in 2025. The regions covered in the congenital heart disease (chd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Congenital Heart Disease (CHD) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15545&type=smp

Browse Through More Reports Similar to the Global Congenital Heart Disease (CHD) Market 2026, By The Business Research Company

Pediatric Heart Valve Repair And Replacement Market Report 2026

https://www.thebusinessresearchcompany.com/report/pediatric-heart-valve-repair-and-replacement-global-market-report

Congenital Heart Defect Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/congenital-heart-defect-devices-global-market-report

Cardiometabolic Diseases Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795